Sonas Pharma Announces Pre Seed Investment Round Backed by SFC Capital and Clarendon Fund Managers

Sonas Pharma, a biotechnology company developing next generation therapeutics for obesity and epilepsy, is delighted to announce the successful closing of its pre seed investment round, led by SFC Capital with participation from Clarendon Fund Managers.
This funding marks an important milestone in Sonas Pharma's mission to build safer, mechanism driven ECS based therapeutics, leveraging modern insights in GPCR pharmacology, peripheral restriction, and rational drug design.
🚀 A Strong Vote of Confidence in Sonas Pharma's Scientific Strategy
The investment will accelerate:
• Advancement of Sonas's CB1 targeting metabolic program, built on neutral, peripherally restricted pharmacology
• Continued development of the company's epilepsy drug discovery platform
• Expansion of core R&D capabilities and early stage translational infrastructure
• Recruitment of key scientific and operational talent
💬 CEO Comment
Chris Hayes, CEO & Co Founder of Sonas Pharma, commented:
"We're thrilled to have the backing of SFC Capital and Clarendon Fund Managers as we build a new generation of ECS therapeutics. Their support validates our mechanism first strategy and allows us to advance programs designed to deliver real clinical impact in two areas of huge unmet medical need in epilepsy and obesity."
💬 Investor Statements
SFC Capital:
"Sonas Pharma stands out with its rigorous scientific foundation and clear strategy for addressing major unmet needs in metabolic and neurological disease. We're excited to support their growth at this early stage." Adam Beveridge, Principal SFC Capital
Clarendon Fund Managers:
"We are delighted to invest in Sonas through the Invest NI-backed Co-Fund and to support the company as it progresses towards important development milestones. Sonas has the foundations to build a best-in-class drug discovery company from Northern Ireland. This investment reflects our continued commitment to supporting ambitious local businesses with global reach."

🌿 About Sonas Pharma
Sonas Pharma is a preclinical biotechnology company focused on developing best-in-class, next generation ECS modulators for high burden metabolic and neurological disorders. By combining validated human biology with precision pharmacology, Sonas aims to bring forward differentiated small molecules designed to be both effective and safe.

About Co-Fund III
Co-Fund III invests alongside private investors on a wholly commercial basis. The £39m fund expects to leverage over £60m from the private sector, opening up more than £100m of investment for Northern Ireland SMEs. Since the first Co-Fund was established in 2011, the fund's investment of £54m has leveraged over £335m from private and public investors into 109 companies, enabling them to create and maintain over 1,600 local jobs and sell their products around the world.

8, Dervaghroy Demesne,
Church Road
Beragh
County Tyrone
Northern Ireland BT79 0GB
Contact Dr Chris Hayes
+44(0)7885317277
chris@sonaspharma.com

Sonas Pharma is a preclinical biotechnology company focused on developing best-in-class, next generation ECS modulators for high burden metabolic and neurological disorders. By combining validated human biology with precision pharmacology, Sonas aims to bring forward differentiated small molecules designed to be both effective and safe.

This release was published on openPR.